Mesenchymal stem cell (MSC)-derived exosomes isolated from Wharton's jelly (WJ) of full-term human umbilical cords represent the most scientifically advanced, immunologically safe, and regulatory-compliant class of regenerative biologic products available in the United States today. When manufactured under current Good Manufacturing Practice (cGMP) conditions pursuant to Section 351(a) of the Public Health Service (PHS) Act, with oversight by the FDA's Center for Biologics Evaluation and Research (CBER), these products occupy a regulatory position that is simultaneously rigorous and commercially defensible. This white paper establishes the scientific, regulatory, and operational case for WJ-MSC exosomes as the gold standard in cell-free regenerative medicine. The analysis spans six core domains: • Scientific superiority of Wharton's jelly as the optimal MSC source • Safety advantages of exosomes over live cell therapies • Section 351(a) classification rationale and the Drug Master File (DMF) Type II pathway • cGMP manufacturing requirements and third-party batch-by-batch virology testing • Cryogenic stability and glass-container shipping standards • Federal and state legal frameworks governing consented clinical use The conclusion is unambiguous: when manufactured properly, tested rigorously, and administered under appropriate legal frameworks with full informed consent, WJ-MSC exosomes produced under 351(a) cGMP standards represent the safest and most efficacious form of regenerative medicine available to U.S. patients.